Compare Intuitive Surgical, Inc. (ISRG) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Invesco Ltd. — how do they compare? Intuitive Surgical, Inc. trades at $341.8 (market cap $123.98B), while Invesco Ltd. trades at $30.5 (market cap $13.34B). The key difference: Intuitive Surgical, Inc. is far larger — about 9.3× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ISRG | IVZ | |
|---|---|---|
Market Cap | $123.98B | $13.34B |
Sector | Health | Financials |
52-Week High | $592.85 | $30.30 |
52-Week Low | $345.42 | $20.45 |
Enterprise Value | $115.35B | $23.59B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $350.06, down 1.34% on the day and near its 52-week low of $344.55. The stock is in a bearish technical trend despite strong fundamentals: Q2 2026 EPS beat estimates at $2.80 vs. $2.48 expected, revenue grew to $10.06B in 2025, and net income margin expanded to 28.45%. However, slowing U.S. procedure growth and a cautious 2026 outlook have pressured shares, with recent news highlighting a nearly 40% decline year-to-date.
The outlook remains mixed: robust profitability and a 69.6% analyst buy rating with a $504.56 consensus target suggest long-term value, but near-term risks include valuation concerns (P/E 40.5), competitive pressures, and macroeconomic headwinds. Investors face a divergence between solid execution and market sentiment driven by growth deceleration fears.
Invesco (IVZ) trades at $30.10, up 1.59% with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 earnings, missing estimates after two consecutive beats. While revenue has grown to $6.38 billion in 2025, net income remains negative at -$281.7 million, though improving from 2023 lows. Analyst consensus shows 42.9% buy ratings with a $30.64 price target, slightly above current levels.
IVZ presents a balanced risk-reward profile with improving operational cash flow ($1.53B in 2025) and positive earnings momentum offset by persistent negative profitability metrics. The stock's valuation appears reasonable with P/E of 19.48 and P/B of 1.35, but investors face execution risks amid competitive asset management pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
